Clinical Trial Update: Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating nivolumab alone or in combination with ipilimumab versus placebo in stage IV malignant melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Prof. Dr. med. Dirk Schadendorf | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED